12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Pauline Houssel-Debry (1) , Audrey Coilly (2, 3) , Claire Fougerou-Leurent (4, 1) , Caroline Jezequel (1) , Christophe Duvoux (5) , Victor de Ledinghen (6) , Sylvie Radenne (7) , Nassim Kamar (8) , Vincent Leroy (9) , Vincent Di Martino (10) , Louis d'Alteroche (11) , Valérie Canva , Filomena Conti , Jerome Dumortier , Hélène Montialoux (12) , Pascal Lebray , Danielle Botta-Fridlund , Albert Tran , Christophe Moreno (13) , Christine Silvain (14) , Camille Besch , Philippe Perre , Claire Francoz (15) , Armando Abergel (16) , François Habersetzer (17) , Maryline Debette-Gratien (18) , Carole Cagnot (19) , Alpha Diallo (19) , Stéphane Chevaliez , Emilie Rossignol (4, 1) , Aurelie Veislinger (4) , Jean-Charles Duclos-Vallee (2, 3) , Georges-Philippe Pageaux

1 CHU Pontchaillou [Rennes]
2 Physiopathologie et traitement des maladies du foie
3 Hôpital Paul Brousse
4 CIC - Centre d'Investigation Clinique [Rennes]
5 CHU Henri Mondor [Créteil]
6 Physiopathologie du cancer du foie
7 Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL]
8 CPTP - Centre de Physiopathologie Toulouse Purpan
9 CHU Grenoble
10 Service d'hépatologie
11 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
12 CHU Rouen
13 ULB - Université libre de Bruxelles
14 CHU Poitiers - Centre hospitalier universitaire de Poitiers
15 Service d'hépatologie
16 CHU Clermont-Ferrand
17 Interactions Virus-Hôte et Maladies Hépatiques
18 Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges]
19 ANRS France Recherche Nord & sud Sida-hiv hépatites

Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).

Keywords: Ribavirin use; treatment duration; ANRS CO23 CUPILT cohort; Direct-acting antiviral agents

Domains: Life Sciences [q-bio]

Pauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, Caroline Jezequel, Christophe Duvoux, et al.. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. Hepatology, 2018, 68 (4), pp.1277-1287. ⟨10.1002/hep.29918⟩. ⟨hal-01807755⟩